Dexo

Dexo is an Israeli biotechnology company focused on developing a next-generation exosome-based platform for the targeted delivery of therapeutic payloads. The company leverages the pioneering research of Prof. Dan Peer in nanomedicine to engineer "Designer Exosomes" that can deliver RNA (mRNA, siRNA) and small molecules with high precision to specific cells. By utilizing the natural properties of exosomes, Dexo aims to overcome the immunogenicity and toxicity challenges associated with synthetic delivery systems like lipid nanoparticles. The company's primary therapeutic focus areas include oncology, inflammation, and rare genetic disorders. Dexo is currently in the pre-clinical stage, advancing its proprietary platform to enable more effective and safer personalized medicines.